Skip to main content
Premium Trial:

Request an Annual Quote

EraGen Raises $12M in Series A Private Equity round

NEW YORK, Jan. 9 (GenomeWeb News) - EraGen Biosciences raised $12 million in Series A financing, the company announced today.

 

Investors in this round included Novartis Venture Fund, First Analysis, Prolog Ventures, Stonehenge Capital, and a syndicate of investors from the Midwest.

 

EraGen also said Tracy Marshbanks from First Analysis and Greg Johnson from Prolog Ventures have joined the company's board of directors.

 

With this funding, the company has raised approximately $21 million to date.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.